Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD123 inhibitor

DRUG CLASS:

CD123 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Hematological Malignancies	No biomarker	Hematological Malignancies	SAR443579 Sensitive: B - Late Trials SAR443579 Sensitive : B	SAR443579 Sensitive: B - Late Trials SAR443579 Sensitive : B
Chr t(14;21)(q22;q22)	Acute Myelogenous Leukemia	Chr t(14;21)(q22;q22)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
PD-L1 underexpression	Acute Myelogenous Leukemia	PD-L1 underexpression	Acute Myelogenous Leukemia	XmAb14045 Sensitive: C3 – Early Trials XmAb14045 Sensitive : C3	XmAb14045 Sensitive: C3 – Early Trials XmAb14045 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	TP53 mutation + Chr del(17p)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
Chr del(17p)	Acute Myelogenous Leukemia	Chr del(17p)	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
CD123 overexpression	Acute Myelogenous Leukemia	CD123 overexpression	Acute Myelogenous Leukemia	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3	MGD006 Sensitive: C3 – Early Trials MGD006 Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3	venetoclax + tagraxofusp-erzs Sensitive: C3 – Early Trials venetoclax + tagraxofusp-erzs Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3	tagraxofusp-erzs Sensitive: C3 – Early Trials tagraxofusp-erzs Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	tagraxofusp-erzs Sensitive: D – Preclinical tagraxofusp-erzs Sensitive : D	tagraxofusp-erzs Sensitive: D – Preclinical tagraxofusp-erzs Sensitive : D
PD-L1 overexpression	Acute Myelogenous Leukemia	PD-L1 overexpression	Acute Myelogenous Leukemia	MGD006 Resistant: D – Preclinical MGD006 Resistant : D	MGD006 Resistant: D – Preclinical MGD006 Resistant : D
CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	MGD024 Sensitive: D – Preclinical MGD024 Sensitive : D	MGD024 Sensitive: D – Preclinical MGD024 Sensitive : D